Literature DB >> 11194894

Bleomycin increases steady-state levels of type I collagen, fibronectin and decorin mRNAs in human skin fibroblasts.

T Yamamoto1, B Eckes, T Krieg.   

Abstract

Bleomycin is a drug capable of inducing tissue fibrosis. In this study, the effects of bleomycin on gene expression of extracellular matrix encoding alpha1(I) collagen, fibronectin and decorin were determined in vitro in human dermal fibroblasts. Northern blot analysis showed that bleomycin upregulated alpha(I) collagen, fibronectin and decorin gene expression dose-dependently between 1 nM and 1 microM. Bleomycin at 100 nM upregulated alpha1(I) collagen, fibronectin and decorin mRNA expression with a peak at 6 h following stimulation in normal skin fibroblast monolayers. Bleomycin enhanced mRNA expression encoding these extracellular matrix proteins in both normal dermal and scleroderma fibroblasts. Concomitant stimulation with bleomycin and interferon-gamma (1,000 U/ml), a representative antifibrotic cytokine, decreased alpha1(I) collagen mRNA expression. Bleomycin also mildly upregulated mRNA expression of transforming growth factor-beta (TGF-beta) and connective tissue growth factor (CTGF) coordinately in normal skin fibroblasts. Our results indicate that bleomycin modulates gene expression of extracellular matrix proteins in dermal fibroblasts, and this effect may be mediated by TGF-beta and CTGF.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11194894     DOI: 10.1007/s004030000180

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  9 in total

1.  alpha2-antiplasmin is associated with the progression of fibrosis.

Authors:  Yosuke Kanno; Eri Kawashita; Misato Minamida; Aki Kaneiwa; Kiyotaka Okada; Shigeru Ueshima; Osamu Matsuo; Hiroyuki Matsuno
Journal:  Am J Pathol       Date:  2009-12-11       Impact factor: 4.307

2.  Phosphatidylinositol-3-kinase/akt regulates bleomycin-induced fibroblast proliferation and collagen production.

Authors:  Yongju Lu; Neelam Azad; Liying Wang; Anand K V Iyer; Vincent Castranova; Bing-Hua Jiang; Yon Rojanasakul
Journal:  Am J Respir Cell Mol Biol       Date:  2009-06-11       Impact factor: 6.914

3.  Vascular changes in bleomycin-induced scleroderma.

Authors:  Toshiyuki Yamamoto; Ichiro Katayama
Journal:  Int J Rheumatol       Date:  2011-10-19

4.  PDGF Promotes Dermal Fibroblast Activation via a Novel Mechanism Mediated by Signaling Through MCHR1.

Authors:  Naoko Takamura; Ludivine Renaud; Willian Abraham da Silveira; Carol Feghali-Bostwick
Journal:  Front Immunol       Date:  2021-11-29       Impact factor: 7.561

Review 5.  The Role of Decorin in Autoimmune and Inflammatory Diseases.

Authors:  Yuanji Dong; Jixin Zhong; Lingli Dong
Journal:  J Immunol Res       Date:  2022-08-17       Impact factor: 4.493

6.  BMP-7 does not protect against bleomycin-induced lung or skin fibrosis.

Authors:  Lynne A Murray; Tillie L Hackett; Stephanie M Warner; Furquan Shaheen; Rochelle L Argentieri; Paul Dudas; Francis X Farrell; Darryl A Knight
Journal:  PLoS One       Date:  2008-12-29       Impact factor: 3.240

Review 7.  Fibrosis in connective tissue disease: the role of the myofibroblast and fibroblast-epithelial cell interactions.

Authors:  Thomas Krieg; David Abraham; Robert Lafyatis
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

8.  Primary effect of chemotherapy on the transcription profile of AIDS-related Kaposi's sarcoma.

Authors:  Antoinette C van der Kuyl; Remco van den Burg; Fokla Zorgdrager; John T Dekker; Jolanda Maas; Carel J M van Noesel; Jaap Goudsmit; Marion Cornelissen
Journal:  BMC Cancer       Date:  2002-09-02       Impact factor: 4.430

9.  Knockout of endothelin type B receptor signaling attenuates bleomycin-induced skin sclerosis in mice.

Authors:  Kengo Akashi; Jun Saegusa; Sho Sendo; Keisuke Nishimura; Takuya Okano; Keiko Yagi; Masashi Yanagisawa; Noriaki Emoto; Akio Morinobu
Journal:  Arthritis Res Ther       Date:  2016-05-21       Impact factor: 5.156

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.